Page last updated: 2024-12-06

sodium thiosulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sodium thiosulfate: do not confuse synonym sodium hyposulfite with sodium hyposulfite, synonym for di-Na salt of dithionous acid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sodium thiosulfate : An inorganic sodium salt composed of sodium and thiosulfate ions in a 2:1 ratio. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID24477
CHEMBL ID3753202
CHEBI ID132112
MeSH IDM0068706

Synonyms (73)

Synonym
sodium thiosulfate
disodium thiosulfate
7772-98-7
thiosulfuric acid, disodium salt
hypo
anhydrous sodium thiosulfate
CHEBI:132112 ,
disodium sulfurothioate
sodium thiosulfate (anhydrous)
sodium oxide sulfide
pedmark
thiosulfuric acid (h2s2o3), disodium salt
sodium thiosulfate, >=99.99% trace metals basis
nsc 45624
chlorine control
hypo (van)
hsdb 592
chlorine cure
ai3-01237
declor-it
einecs 231-867-5
sodothiol
antichlor
thiosulfuric acid (h2s2o3), sodium salt (1:2)
ec 231-867-5
unii-l0iyt1o31n
l0iyt1o31n ,
ins no.539
e-539
sodium thiosulfate, anhydrous
ins-539
sodium thiosulphate, anhydrous
sodium thiosulfate [who-dd]
sodium thiosulfate [mi]
sodium thiosulfate [hsdb]
disodium thiosulphate
sodium thiosulfate anhydrous [ii]
AKOS015856704
na2o3s2
BP-21059
AKOS016372312
AKHNMLFCWUSKQB-UHFFFAOYSA-L
sodium thio-sulfate
sodiumthiosulfate
sodium thiosulfat
na2s2o3
FT-0696570
DTXSID9042417 ,
mfcd00003499
CHEMBL3753202
sodium thiosulfate, purum p.a., anhydrous, >=98.0% (rt)
hypo alcohol, in ethanol
sodium thiosulfate, reagentplus(r), 99%
sodium thiosulfate, saj first grade, >=90.0%
sodium thiosulfate, ar, >=98%
sodium thiosulfate, lr, >=97%
sodium thiosulfate, vetec(tm) reagent grade, 99%
sodium thiosulfate, p.a., 98.0%
sodium thiosulfate, anhydrous, trace metals grade 99.99%
sodium sulfothioate
Q339866
sodothiol; sulfactol; sulfothiorine
D78333
disodium;dioxido-oxo-sulfanylidene-lambda6-sulfane
O0522
sodium hyposulfit
thiosulfate, sodium, pentahydrate
sodium thiosulfate anhydrous (ii)
cyanide antidote package
sulfothiorine
sodium sulfurothioate hydrate (2:1:5)
dtxcid4024197
dtxcid7022417

Research Excerpts

Overview

Sodium thiosulfate (Na2S2O3) is a clinically established drug with antioxidant and sulphide-releasing properties. It is a traditional medicine used in the rescue of cyanide poisoning, and some pruritus dermatosis.

ExcerptReferenceRelevance
"Sodium thiosulfate (STS) is a traditional medicine used in the rescue of cyanide poisoning, and some pruritus dermatosis."( Sodium thiosulfate ameliorates atopic dermatitis via inhibiting the activation of NLRP3 inflammasome.
Li, X; Liu, Y; Lu, J; Wang, D; Yang, S; Zeng, Y; Zong, X, 2023
)
3.07
"Sodium thiosulfate (Na2S2O3) is a clinically established drug with antioxidant and sulphide-releasing properties. "( Effects of Sodium Thiosulfate During Resuscitation From Trauma-and-Hemorrhage in Cystathionine Gamma Lyase (CSE) Knockout Mice.
Abdelsalam, E; Calzia, E; Denoix, N; Gröger, M; Hoffmann, A; Hogg, M; Kress, S; McCook, O; Merz, T; Nussbaum, BL; Radermacher, P; Saub, V; Stahl, B; Vogt, JA; Wachter, U; Wang, R; Wolfschmitt, EM, 2022
)
2.55
"Sodium thiosulfate (STS) is a potent drug used to treat calcific uremic arteriopathy in dialysis patients and its mode of action is envisaged by calcium chelation and antioxidant potential. "( Renal mitochondria can withstand hypoxic/ischemic injury secondary to renal failure in uremic rats pretreated with sodium thiosulfate.
Balasubramanian, ED; Kurian, GA; Mohan, D; Ravindran, S,
)
1.78
"Sodium thiosulfate (STS) is an industrial chemical which has also been approved for the treatment of certain rare medical conditions. "( Sodium thiosulfate attenuates glial-mediated neuroinflammation in degenerative neurological diseases.
Lee, M; McGeer, EG; McGeer, PL, 2016
)
3.32
"Sodium thiosulfate is an antioxidant shown in preclinical studies in animals to prevent cisplatin-induced hearing loss with timed administration after cisplatin without compromising the antitumour efficacy of cisplatin. "( Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
Bliss, B; Chen, L; Freyer, DR; Knight, K; Krailo, MD; Lange, B; Neuwelt, EA; Pollock, BH; Ramdas, J; Sung, L; Van Hoff, D; VanSoelen, ML; Villaluna, D; Wiernikowski, J, 2017
)
2.29
"Sodium thiosulfate (STS) is a U.S. "( The effect of sodium thiosulfate administration on nephrocalcinosis in a rat model.
LaGrange, CA; Lele, SM; Pais, VM, 2009
)
2.16
"Sodium thiosulfate was not found to be an effective reducing agent for the acute treatment of methemoglobinemia."( Sodium thiosulfate fails to reduce nitrite-induced methemoglobinemia in vitro.
Matteucci, MJ; Reed, WJ; Tanen, DA, 2003
)
3.2
"Sodium thiosulfate was found to be an effective antidote in the rat enabling rapid normalization of hypoxia markers and clearing of cyanide from arterial blood."( [Sodium thiosulfate for acute cyanide poisoning: study in a rat model].
Baud, FJ; Borron, SW; Renard, C; Renaudeau, C, 2005
)
1.96
"Sodium thiosulfate (STS) is a potent nucleophile and in initial experiments was found to inhibit mutagenesis resulting from exposure of Salmonella typhimurium strain TA100 to the direct-acting carcinogens beta-propiolactone and styrene oxide."( Inhibition of beta-propiolactone-induced mutagenesis and neoplasia by sodium thiosulfate.
Galbraith, AR; Hochalter, JB; Wattenberg, LW, 1987
)
1.23
"Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage."( High-dose cisplatin with sodium thiosulfate protection.
Andrews, PA; Felthouse, RD; Howell, SB; Markman, M; Murphy, MP; Pfeifle, CE; Woliver, TB, 1985
)
1.29

Effects

Sodium thiosulfate (STS) has been shown experimentally to protect against cisplatin-induced renal insufficiency by inactivating the nephrotoxic as well as cytotoxic properties. The agent has been proven efficacious in models of urolithiasis and vascular calcification.

ExcerptReferenceRelevance
"Sodium thiosulfate has a marked correlation effect."( [Glutamate dehydrogenase activity in the pancreatic tissue in acute experimental pancreatitis and under the action of sodium thiosulphate].
Gevorkian, DA; Saakian, IL; Simavorian, PS, 1991
)
1
"Sodium thiosulfate therapy has proven to be effective and tolerated."( Multifaceted approach to a rare clinical case of calciphylaxis in a renal transplant recipient.
Bellasi, A; Feriozzi, S; Gomes, V; Massimetti, C; Modoni, A, 2019
)
1.24
"Sodium thiosulfate (STS) has recently been used with success in the treatment of tumoral calcinosis."( Tolerance and effect of sodium thiosulfate in calcific tendinitis of the rotator cuff.
Bertrand-Vasseur, A; Darrieurtort-Laffite, C; Garraud, T; Le Goff, B; Planche, L, 2020
)
1.59
"Sodium thiosulfate (STS) has of late been proven efficacious in models of urolithiasis and vascular calcification. "( Sodium Thiosulfate Preconditioning Ameliorates Ischemia/Reperfusion Injury in Rat Hearts Via Reduction of Oxidative Stress and Apoptosis.
Boovarahan, SR; Kurian, GA; Ravindran, S; Shanmugam, K; Vedarathinam, RC, 2017
)
3.34
"Sodium thiosulfate (STS) has shown promising effects in amelioration of myocardial ischemia-reperfusion injury (IR) in a rat model and is clinically useful in the treatment of chronic kidney disease (CKD) associated calciphylaxis. "( Sodium thiosulfate mediated cardioprotection against myocardial ischemia-reperfusion injury is defunct in rat heart with co-morbidity of vascular calcification.
Kurian, GA; Ramachandran, K; Ravindran, S, 2018
)
3.37
"Sodium thiosulfate (STS), which has been proven to be effective in the treatment of uremic calciphylaxis, shows promise; however, reports of its use in non-uremic cases are limited."( Sodium thiosulfate in the treatment of non-uremic calciphylaxis.
Castellanos, EH; Dahir, KM; McGirt, LY; Ning, MS, 2013
)
2.55
"Sodium thiosulfate (STS) has been shown to reduce the progression of uremic calcifications in haemodialysis patients."( [Is the Sodium Thiosulfate Therapy useful for vascular calcification in dialysis Pts?].
Duranti, E; Ghiandai, G; Imperiali, P; Ralli, C; Zingarelli, A,
)
1.29
"Sodium thiosulfate (STS) has been shown to be an effective treatment in calcification disorders such as calciphylaxis and vascular calcification."( Sodium Thiosulfate Prevents Chondrocyte Mineralization and Reduces the Severity of Murine Osteoarthritis.
Busso, N; Ea, HK; Lioté, F; Nasi, S; So, A, 2016
)
2.6
"Sodium thiosulfate has been shown to produce clinical improvement of calciphylaxis lesions."( Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis.
Raymond, CB; Wazny, LD, 2008
)
2.51
"Sodium thiosulfate (STS) has been shown to be an antioxidant and calcium solubilizer, but the possible role of STS in dysfunctional ventricles remains unknown. "( Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation.
Hayden, MR; Hughes, WM; Kumar, M; Metreveli, N; Moshal, KS; Sen, U; Tyagi, N; Tyagi, SC; Vacek, TP, 2008
)
2.09
"Sodium thiosulfate has been successfully used to treat calcyphilaxis in adults and children, but its effect on iatrogenic calcinosis cutis secondary to extravasation of calcium solutions is less known. "( Successful treatment of severe iatrogenic calcinosis cutis with intravenous sodium thiosulfate in a child affected by T-acute lymphoblastic leukemia.
Angelo, R; Annapaola, C; Giuseppe, L; Raffaella, C; Simone, C; Tullio, I,
)
1.8
"Sodium thiosulfate has recently been used as a novel treatment option for calciphylaxis because of its dual role as an antioxidant and a chelator."( Sodium thiosulfate not always resolves calciphylaxis: an ambiguous response.
Di Raimondo, D; La Placa, S; Li Vecchi, M; Licata, G; Miceli, S; Milio, G; Pinto, A; Tuttolomondo, A, 2011
)
2.53
"Sodium thiosulfate (STS) has reported efficacy, thought to be because solubilizing calcium deposits promote clearance by hemodialysis (HD)."( Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis.
Derendorf, H; Ross, EA; Singh, RP, 2011
)
1.43
"Sodium thiosulfate has been used to systemically treat calciphylaxis with little to no adverse effects. "( A novel treatment for ulcerative calcinosis cutis.
Bair, B; Fivenson, D, 2011
)
1.81
"Sodium thiosulfate (STS) has been described as a protective agent against CDDP toxicity, but it also reduces CDDP's antitumoral cytotoxicity."( Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig.
Fetoni, A; Guitton, MJ; Lloyd Faulconbridge, RV; Puel, JL; Pujol, R; Wang, J, 2003
)
1.36
"Sodium thiosulfate therapy has been proposed for calcific uremic arteriolopathy and nephrogenic systemic fibrosis in hemodialysis patients. "( Measuring plasma conductivity to detect sodium load in hemodialysis patients.
Deray, G; Isnard-Bagnis, C; Mercadal, L; Petitclerc, T; Renault, N; Servais, A; Venditto, M, 2008
)
1.79
"Sodium thiosulfate has a marked correlation effect."( [Glutamate dehydrogenase activity in the pancreatic tissue in acute experimental pancreatitis and under the action of sodium thiosulphate].
Gevorkian, DA; Saakian, IL; Simavorian, PS, 1991
)
1
"Sodium thiosulfate has been shown experimentally to protect against cisplatin-induced renal insufficiency by inactivating the nephrotoxic as well as cytotoxic properties of the agent. "( Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection.
Cleary, S; Howell, SB; Markman, M, 1985
)
1.71

Treatment

Sodium thiosulfate (STS) blocked carboplatin cytotoxicity against the LX-1 human small cell lung carcinoma cell line in vitro. Treatment transiently lowered plasma ionized calcium and induced metabolic acidosis.

ExcerptReferenceRelevance
"Sodium thiosulfate treatment transiently lowered plasma ionized calcium and induced metabolic acidosis."( Sodium thiosulfate prevents vascular calcifications in uremic rats.
Farese, S; Frey, BM; Frey, FJ; Huynh-Do, U; Pasch, A; Schaffner, T, 2008
)
2.51
"Treatment with sodium thiosulfate provides good results; however, intralesional and intravenous treatment can be limited by its adverse effects."( Therapeutic success of sodium thiosulfate in treating cutaneous calciphylaxis in a patient with hyperphosphataemic familial tumoral calcinosis.
Gómez, C; Morales, P; Requena, S; Santos-Juanes, J, 2022
)
1.37
"Treatment with sodium thiosulfate was given for 8 patients, and was beneficial for all after a mean duration of 3.4 months."( [Incidence and characteristics of calciphylaxis in Martinique (2006-2012)].
Aoun, A; Banydeen, R; Baubion, E; Derancourt, C; Djiconkpode, I; Dueymes, JM; Ekindi, N; Quist, D; Riaux, A; Sadreux, T; Ureña-Torres, P, 2014
)
0.74
"Treatment with sodium thiosulfate was beneficial for 8 patients."( [Incidence and characteristics of calciphylaxis in Martinique (2006-2012)].
Aoun, A; Banydeen, R; Baubion, E; Derancourt, C; Djiconkpode, I; Dueymes, JM; Ekindi, N; Quist, D; Riaux, A; Sadreux, T; Ureña-Torres, P, 2014
)
0.74
"Treatment with sodium thiosulfate resulted in dramatic scintigraphic improvement."( Bone scan findings in metastatic calcification from calciphylaxis.
Leslie, WD; Soni, S, 2008
)
0.69
"Treatment with sodium thiosulfate (STS) and hyperbaric oxygen (HBO) therapy alone was ineffective, forcing the patient to undergo bilateral below the-knee-amputation (BKA) 5 months after presentation."( Successful treatment of calcific uremic arteriolopathy in a pediatric dialysis patient.
Amin, N; Gonzalez, E; Lieber, M; Salusky, IB; Zaritsky, JJ, 2010
)
0.7
"Treatment with sodium thiosulfate (STS) blocked carboplatin cytotoxicity against the LX-1 human small cell lung carcinoma cell line in vitro."( In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity.
Brummett, RE; Guitjens, S; Kroll, RA; McCormick, CI; Muldoon, LL; Neuwelt, EA; Pagel, MA; Remsen, LG, 1996
)
0.92

Toxicity

ExcerptReferenceRelevance
"Renal dysfunction and urinary disorders are the most troublesome adverse reaction to anticancer agents such as cisplatin (CDDP) and ifosfamide (IFM)."( [New treatments for urogenital toxicity of anti-neoplastic chemotherapy].
Hirosawa, A; Niitani, H; Shibuya, M, 1990
)
0.28
"Nephrotoxicity is a relatively common and potentially serious adverse effect of treatment with certain cytotoxic drugs (especially ifosfamide)."( Strategies to prevent nephrotoxicity of anticancer drugs.
Skinner, R, 1995
)
0.29
"Cisplatin is a nephrotoxic drug; however, agents that may make cisplatin therapy more safe and rewarding will be available in the near future."( Newer insights into cisplatin nephrotoxicity.
Anand, AJ; Bashey, B, 1993
)
0.29
"The toxicity of the herbicide paraquat in mice, measured by the single dose LD50 after 7 days, was significantly decreased by coinjection of thiosulfite (1 g/kg; one time per day for 3 days) or sulfite (0."( Protection against paraquat-induced toxicity with sulfite or thiosulfate in mice.
Yamamoto, H, 1993
)
0.29
" No other clinically significant adverse effects were noted."( Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers.
Becker, CE; Benowitz, NL; Forsyth, JC; Hall, AH; Mueller, PD; Osterloh, J; Rumack, BH, 1993
)
0.29
") increased LD50 values of CN(8."( Antidotal effect of dihydroxyacetone against cyanide toxicity in vivo.
Niknahad, H; O'Brien, PJ, 1996
)
0.29
" While control ewes and fetuses suffered progressive increases in red cell cyanide concentrations into the toxic range, experimental ewes and fetuses never developed toxic red cell cyanide levels (ewes P < ."( Prevention of fetal and maternal cyanide toxicity from nitroprusside with coinfusion of sodium thiosulfate in gravid ewes.
Carlton, MW; Curry, SC; Raschke, RA, 1997
)
0.52
"We have previously reported that the thiol compound tiopronin protects rat kidneys in vitro against the toxic activity of cisplatin."( Cisplatin combined with tiopronin or sodium thiosulfate: cytotoxicity in vitro and antitumor activity in vivo.
Esposito, M; Lindup, WE; Mariggiò, MA; Pastrone, I; Viale, M; Zhang, JG, 1999
)
0.58
" We presently report the safe coadministration of intraventricular sodium nitroprusside and thiosulfate in 10 patients with secured ruptured cerebral aneurysms in the intensive care unit, without the use of cerebral angiography for vasospasm treatment."( Safety of intraventricular sodium nitroprusside and thiosulfate for the treatment of cerebral vasospasm in the intensive care unit setting.
McGinnis, G; Thomas, JE, 2002
)
0.31
" The toxicological causality of this complex mixture differed for each PW with nonpolar organics being consistently toxic in all samples."( Application of toxicity identification evaluation procedures for characterizing produced water using the tropical mysid, Metamysidopsis insularis.
Agard, JB; Elias-Samlalsingh, N, 2004
)
0.32
" However, metals in sewage sludge might accumulate in soil after repeated sludge applications, and metal concentrations might reach concentrations that are toxic to microorganisms, soil organisms and/or plants."( Identification of metal toxicity in sewage sludge leachate.
Ahlberg, G; Dave, G; Fjällborg, B; Nilsson, E, 2005
)
0.33
" However, in both treatment arms, the incidence expressed in National Cancer Institute Common Terminology Criteria of Adverse Events (version 3) did not deviate (P > ."( Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Balm, AJ; Dreschler, WA; Hart, AA; Lansdaal, PE; Rasch, CR; Schornagel, JH; Simis, YJ; Zuur, CL, 2007
)
0.34
"STS treatment is feasible, appears safe and may decrease the rate of progression of vascular calcification in hemodialysis patients."( Effects of sodium thiosulfate on vascular calcification in end-stage renal disease: a pilot study of feasibility, safety and efficacy.
Bierhals, A; Cabellon, A; Davila-Roman, VG; de Las Fuentes, L; Delmez, JA; Mathews, SJ; Podaralla, P; Slatopolsky, E; Spence, K; Zheng, S, 2011
)
0.76
" The cassava root contains wastewater, popularly known as manipueira, which is a toxic substance."( Mutagenicity and cytotoxicity of liquid waste, press water and pond water, produced in the cassava flour industry, and of antitoxic sodium thiosulfate.
Düsman, E; Viana, LÁ; Vicentini, VE, 2014
)
0.61
" In the case of Pseudokirchneriella subcapitata, manganese dioxide powder should be used as an alternative quenching agent to catalase, since this enzyme exhibited a highly toxic effect towards these microalgae."( Investigation of the toxicity of common oxidants used in advanced oxidation processes and their quenching agents.
Arslan-Alaton, I; Dursun, D; Olmez-Hanci, T, 2014
)
0.4
" Careful monitoring for adverse transient side effects is advised."( Successful treatment of calciphylaxis with intravenous sodium thiosulfate in a nonuremic patient: case report and review of therapy side effects.
Fernandes, C; Hanna, D; Maynard, B, 2014
)
0.65
" These investigations revealed that a highly toxic CP-derived hydrolysis product - the highly toxic monoaqua hydrolysis complex (MHC) - is formed within 5min."( Improving the safety of metal-based drugs by tuning their metabolism with chemoprotective agents.
Gailer, J, 2018
)
0.48
"Our trial suggests that STS deposited on the round window was safe for the middle and inner ears."( A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
Bairati, I; Bussières, R; Côté, M; Guitton, MJ; Leclerc, M; Meyer, F; Philippon, D; Rolland, V, 2019
)
0.74
"Despite ototoxicity being a prevalent consequence of cisplatin chemotherapy, little guidance exists on interventions to prevent this permanent and progressive adverse event."( Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.
Brock, PR; Cabral, S; Chang, KW; Dupuis, LL; Epelman, S; Freyer, DR; Knight, K; Mills, D; Phillips, R; Potter, E; Risby, D; Robinson, PD; Simpkin, P; Sullivan, M; Sung, L, 2020
)
0.56
" Ototoxicity and subsequent permanent hearing loss remain a serious dose-limiting side effect associated with cisplatin treatment."( Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients.
Hu, QY; Keilty, J; Kropp, J; McCarthy, R; Ren, Y; Shi, F; Soglia, J; Viglietta, V; Weber, P; Wolff, H, 2020
)
0.56
" None of the patients reached the primary endpoint, nor experienced a serious adverse event."( Safety and Tolerability of Sodium Thiosulfate in Patients with an Acute Coronary Syndrome Undergoing Coronary Angiography: A Dose-Escalation Safety Pilot Study (SAFE-ACS).
Assa, S; de Koning, MLY; Lipsic, E; Maagdenberg, CG; Pasch, A; van der Harst, P; van Goor, H; van Veldhuisen, DJ, 2020
)
0.86
" Grade 1 adverse events were reported."( Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.
Balm, AJM; Beijnen, JH; Burgers, JA; de Boer, JP; de Weger, VA; Dreschler, WA; Duinkerken, CW; Hauptmann, M; Marchetti, S; Nuijen, B; Pluim, D; Rosing, H; Schellens, JHM; van der Molen, L; Zuur, CL, 2021
)
0.98
"Transtympanic application of STS was safe and feasible."( Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.
Balm, AJM; Beijnen, JH; Burgers, JA; de Boer, JP; de Weger, VA; Dreschler, WA; Duinkerken, CW; Hauptmann, M; Marchetti, S; Nuijen, B; Pluim, D; Rosing, H; Schellens, JHM; van der Molen, L; Zuur, CL, 2021
)
0.98
"Silver is a transition metal that is known to be less toxic than platinum."( The selective cytotoxicity of silver thiosulfate, a silver complex, on MCF-7 breast cancer cells through ROS-induced cell death.
Mori, K; Ota, A; Sato, H; Sato, VH; Sugiyama, E; Tajima, M, 2021
)
0.62
" The results show that replacement of the aqua ligand with thiosulfate renders the complex less toxic most likely by distrupting its cellular entry."( The effect of sodium thiosulfate on cytotoxicity of a diimine Re(I) tricarbonyl complex.
Capper, MS; Enriquez Garcia, A; Gelfand, BS; Jalilehvand, F; Lai, B; Shemanko, CS; Wang, BO, 2021
)
0.98
"To evaluate the association between concurrent STS and reduced risk of ototoxic effects among patients undergoing platinum-based chemotherapy and to evaluate outcomes, including event-free survival, overall survival, and adverse outcomes."( Association of Sodium Thiosulfate With Risk of Ototoxic Effects From Platinum-Based Chemotherapy: A Systematic Review and Meta-analysis.
Chang, CY; Chen, CH; Cheng, YF; Huang, CY; Lin, HH; Wang, MC, 2021
)
0.97
"Doxorubicin (DOX) is an effective antitumor agent, but its clinical usage is limited due to adverse cardiotoxic effects."( Cardioprotective effects of sodium thiosulfate against doxorubicin-induced cardiotoxicity in male rats.
Abdollahi, A; Dehpour, AR; Ghafari, H; Ghazi-Khansari, M; Gortany, NK; Khalilzadeh, M; Shekari, M, 2022
)
1.02

Pharmacokinetics

ExcerptReferenceRelevance
" As a result, 1) the level of free-CDDP in ascites fluid was significantly elevated after administration, showing that free-CDDP possessing anti-tumor activity persisted in the ascites fluid for a long time and reached the peak concentration 30 minutes after administration."( [Pharmacokinetics following intraperitoneal infusion of cisplatinum with and without sodium thiosulfate rescue in carcinomatous peritonitis in advanced gastric cancers].
Kou, Y; Nakayoshi, A; Namatame, K, 1991
)
0.51
" This study demonstrates a pharmacokinetic advantage of intraperitoneal chemotherapy with cDDP and an effectiveness against peritoneal carcinosis from various malignancies with minimal systemic toxicity."( [Effective treatment of peritoneal carcinosis by intraperitoneal cis-diamminedichloroplatinum (c-DDP) administration with systemic sodium thiosulfate protection. Clinical results and pharmacokinetics].
Ehninger, G; Jakob, F; Rückle, H; Wilms, K, 1986
)
0.48
" This pilot study demonstrates a pharmacokinetic advantage of ip chemotherapy with c-DDP and an effectiveness against peritoneal carcinosis."( [Therapy of peritoneal carcinosis with intraperitoneal administration of cis-diamminedichloroplatinum and systemic sodium thiosulfate protection. Clinical results of a pilot study and pharmacokinetics].
Ehninger, G; Haag, C; Rückle, H; Wilms, K, 1985
)
0.48
"45 micrograms/ml and the half-life was 53 minutes."( [Pharmacokinetic study of cisplatin and sodium thiosulfate in two-route-infusion chemotherapy].
Ikeda, K, 1986
)
0.54
" To gain insight into the mechanism of action of thiosulfate on cyanide toxicity, a pharmacokinetic analysis of cyanide distribution and metabolism with and without sodium thiosulfate was conducted in mongrel dogs."( Effects of thiosulfate on cyanide pharmacokinetics in dogs.
Hayton, WL; Morgan, RL; Sylvester, DM; Way, JL, 1983
)
0.46
"The safety, efficacy and pharmacokinetic parameters of 5 g of hydroxocobalamin given intravenously, alone or in combination with 12."( Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers.
Becker, CE; Benowitz, NL; Forsyth, JC; Hall, AH; Mueller, PD; Osterloh, J; Rumack, BH, 1993
)
0.29
" The method was successfully applied to study the pharmacokinetic of PVP-I in rabbits after vaginal administration."( Optimization and validation of an ion-pair RP-HPLC-UV method for the determination of total free iodine in rabbit plasma: application to a pharmacokinetic study.
Cui, L; Fan, G; Wang, S; Wen, J; Zhou, T, 2009
)
0.35

Compound-Compound Interactions

Two-route chemotherapy (TRC) using cis-diamminedichloroplatinum(II) (DDP) and its antidote, sodium thiosulfate (STS), combined with the angiotensin II (AT-II)-induced hypertension method was evaluated for its efficacy against peritoneally disseminated tumors.

ExcerptReferenceRelevance
""Two-route chemotherapy" (TRC) using cis-diamminedichloroplatinum(II) (DDP) and its antidote, sodium thiosulfate (STS), combined with the angiotensin II (AT-II)-induced hypertension method was evaluated for its efficacy against peritoneally disseminated tumors in rats."( "Two-route chemotherapy" using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulfate, combined with angiotensin II is effective against peritoneally disseminated cancer in rats.
Aoki, K; Baba, T; Hasuda, K; Kobayashi, H; Kuroiwa, T; Taniguchi, S, 1989
)
0.72
" STS in a rat liver tumor, we made use of the AT-II-induced hypertension method, in combination with TRC."( Efficacy of two-route chemotherapy using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulfate, in combination with angiotensin II for rat liver tumor.
Aoki, K; Baba, T; Hasuda, K; Kobayashi, H; Taniguchi, S, 1989
)
0.5
"Ten patients with carcinomatous peritonitis of gastrointestinal cancer have been treated with administrations of CDDP-Ip (50-150 mg/body), in combination with systemic chemotherapy simultaneously combined with sodium thiosulfate (STS) iv in 4 patients."( [Intraperitoneal (Ip) administration of cisplatin in combination with systemic chemotherapy in patients with malignant ascites of gastrointestinal cancer: clinical evaluation and pharmacokinetics].
Fukushi, A; Hirayama, M; Koda, K; Kure, T; Morita, K; Nakazawa, O; Takahashi, H; Terada, S; Terui, T; Yoshizaki, N, 1988
)
0.46
" Within the frames of synergoantagonism interplay, the drug combination produced on some of the reactions an effect which was similar to that exerted by one of the components."( [Characteristics of the effect of drug combinations on the development of immediate hypersensitivity].
Chetverikov, GN,
)
0.13
"The effect of methoxime combined with a) atropine, b) benactyzine, c) atropine and natrium thiosulphate, d) atropine and diazepam on antidotal treatment effectiveness was studied in tabun-poisoned mice."( Effect of methoxime combined with anticholinergic, anticonvulsant or anti-HCN drugs in tabun-poisoned mice.
Sevelová, L; Vachek, J, 2003
)
0.32

Bioavailability

ExcerptReferenceRelevance
"Given the low and variable bioavailability of oral STS, only intravenous STS should be prescribed today."( Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers.
Farese, S; Frey, BM; Frey, FJ; Hildebrandt, T; Kalicki, R; Pasch, A; Stauffer, E; Uehlinger, DE, 2011
)
1.81
" We have shown that aquohydroxocobinamide is a potent cyanide antidote in animal models of cyanide poisoning, but it is unstable in solution and poorly absorbed after intramuscular injection."( Nitrocobinamide, a new cyanide antidote that can be administered by intramuscular injection.
Boss, GR; Brenner, M; Burney, T; Chan, A; Fridman, A; Green, C; Guo, LT; Haushalter, KJ; Jiang, J; Lee, J; Liu, MT; Mahon, SB; Mukai, D; Patel, HH; Pilz, RB; Shelton, GD; Yoon, D, 2015
)
0.42
" Even though pharmacokinetic studies show poor bioavailability of oral STS, we report successful use of oral STS in 2 PD patients with calciphylaxis."( Treatment of Calciphylaxis: A Case for Oral Sodium Thiosulfate.
Klein, J; Shetty, A,
)
0.39
" However, a simple and uniform method for investigating HgS bioavailability is still lacking."( Assessment of the Bioavailability of Mercury Sulfides in Paddy Soils Using Sodium Thiosulfate Extraction - Results from Microcosm Experiments.
Bai, X; Gao, Y; Lei, P; Li, H; Li, Y; Sha, S; Tang, W; Xu, D; Zhao, J; Zhong, H, 2022
)
0.95

Dosage Studied

Intravenous sodium thiosulfate was well tolerated and gave effective therapy in hepatocellular carcinoma. Cytochrome redox responses were not altered either in magnitude or kinetics by hyperoxia. The cyanide-cytochrome dose-response curve was greatly shifted to the right by pretreatment with sodium nitrite.

ExcerptRelevanceReference
" Nitrite should not be given if the poisoning is mild or diagnosis is uncertain, to avoid excessive methemoglobin, dosage of sodium nitrite must be adjusted according to hemoglobin level (Table 1)."( Acute cyanide poisoning: a case report with toxicokinetic study.
Kaojarern, S; Wananukul, W, 1992
)
0.28
"Ovarian carcinoma demonstrates a steep dose-response curve for cisplatin, but even very small levels of acquired resistance at the cellular level are sufficient to block the efficacy of intravenous (IV) cisplatin."( Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma.
Braly, P; Howell, SB; Kim, S; Kirmani, S; McClay, EF; Plaxe, S, 1991
)
0.28
" Therapeutic strategies aimed at reducing toxicity and allowing dose escalation of intravenous cisplatin, such as administration in hypertonic saline and pharmacokinetically based dosing schedules, have been partially successful in reducing nephrotoxicity and bone marrow suppression."( Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate.
DeGregorio, MW; Gandara, DR; Makuch, RW; Perez, EA; Wiebe, VJ, 1990
)
0.54
" Afterwards, sodium thiosulphate was given additionally for 24 h at a dosage of 1 g per hour."( [Cyanide poisoning: treatment with hyperoxygenation and sodium thiosulphate].
Bock, TA; Heintz, B; Kierdorf, H; Sieberth, HG, 1990
)
0.28
" High dosage arterial infusion of CDDP and angiotensin II and intravenous injection of sodium thiosulfate was well tolerated and gave effective therapy in hepatocellular carcinoma."( Intra-arterial cis-platinum infusion with sodium thiosulfate protection and angiotensin II induced hypertension for treatment of hepatocellular carcinoma.
Itoh, Y; Kobayashi, H; Onohara, S; Shinohara, S,
)
0.62
" The antagonism of both receptor types was reversible since washing of the tissues after incubation with DMPEA brought the agonist dose-response curve back to the control value."( Alpha-adrenoceptor occupancy by N,N-dimethyl-2-bromo-2-phenethylamine hydrobromide (DMPEA) in rat vas deferens.
Brasili, L; Cassinelli, A; Giardinà, D; Gulini, U; Melchiorre, C; Quaglia, W, 1988
)
0.27
" Thiosulfate dosing studies showed that a molar excess of at least 200:1 (Na2S2O3:HN2) was required for significant antidotal activity."( Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse.
Alberts, DS; Dorr, RT; Soble, M, 1988
)
0.65
" Results of oral dose-response studies utilizing a 1:1 (w/w) mixture of acetonitrile and acetone, or varying doses of acetonitrile administered together with a constant dose of acetone, indicated that acetone potentiated acute acetonitrile toxicity three- to fourfold in rats."( Acetone potentiation of acute acetonitrile toxicity in rats.
Freeman, JJ; Hayes, EP, 1985
)
0.27
" Cytochrome redox responses were not altered either in magnitude or kinetics by hyperoxia; however, the cyanide-cytochrome dose-response curve was greatly shifted to the right by pretreatment with sodium nitrite, and the recovery rate of cytochrome a,a3 from cyanide-induced reduction was enhanced fourfold by pretreatment with sodium thiosulfate."( Cyanide-induced cytochrome a,a3 oxidation-reduction responses in rat brain in vivo.
Jöbsis, FF; Piantadosi, CA; Sylvia, AL, 1983
)
0.44
" dosing or 3 and 8 h after repeated oral dosing in the coadministered group were significantly decreased as compared with those in the group received warfarin alone."( Effect of digoxin on plasma clearance and anticoagulant effect of warfarin in rats.
Iwaki, M; Konishi, Y; Ogiso, T, 1984
)
0.27
" Infusion of SNP mixed with thiosulphate showed no such accumulation of cyanide in any patient, irrespective of dosage level and duration."( Cyanide toxicity of sodium nitroprusside in therapeutic use with and without sodium thiosulphate.
Busse, J; Gross, R; Loeschcke, G; Pasch, T; Schulz, V, 1982
)
0.26
"Several randomized trials of various malignancies treated with cisplatin indicate a dose-response relationship with higher MST and longer survival achieved with high-dose compared to standard dose cisplatin regimens."( Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
Malmström, H; Rasmussen, S; Simonsen, E, 1993
)
0.29
" Two separate protocols differing in dosage frequency were used, depending on the presence or absence of a new neurological deficit."( Safety of intraventricular sodium nitroprusside and thiosulfate for the treatment of cerebral vasospasm in the intensive care unit setting.
McGinnis, G; Thomas, JE, 2002
)
0.31
"Our results show that the survival frequency is strongly influenced by MMS dosage and exposure time."( Chemoprotection profiles of sodium thiosulfate on methyl methanesulfonate-induced mutagenesis of bacteriophage T4.
Khan, AU; Lal, SK; Malik, A, 2002
)
0.61
" STS dosage was 25 g/1."( Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults.
Araya, CE; Dharnidharka, VR; Fennell, RS; Neiberger, RE, 2006
)
1.78
" Therefore, to establish a dose-response curve, the times required for recovery of this righting reflex with increasing doses of cyanide were measured."( A novel paradigm for assessing efficacies of potential antidotes against neurotoxins in mice.
Briggs, JE; Crankshaw, DL; DeLong, D; Goon, DJ; Kuskowski, M; Nagasawa, HT; Patterson, SE, 2007
)
0.34
" Further research is necessary to fully describe the optimal use of sodium thiosulfate, bisphosphonates, and cinacalcet for the treatment of calciphylaxis, including their pharmacokinetics in adults with CKD, optimal dosing strategies, and duration of therapy."( Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis.
Raymond, CB; Wazny, LD, 2008
)
2.02
" Lack of rigorous pharmacokinetic studies makes it problematic for determining proper STS dosing given the expanding range of dialysis prescriptions and intensities."( Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis.
Derendorf, H; Ross, EA; Singh, RP, 2011
)
0.71
"The purpose of this study was to determine the dosing strategies for STS during different dialysis regimens."( Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis.
Derendorf, H; Ross, EA; Singh, RP, 2011
)
0.71
"Based on the success reported for one STS dosing regimen and assuming area under the curve exposure of STS is proportional to its effect, pharmacokinetic simulations can be used to calculate the dose for alternative, higher or lower intensity dialysis regimens."( Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis.
Derendorf, H; Ross, EA; Singh, RP, 2011
)
0.71
" The biologic relevance of the high hemodialysis clearance for the optimal time point of STS dosing awaits clarification of the mechanisms of action of STS."( Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers.
Farese, S; Frey, BM; Frey, FJ; Hildebrandt, T; Kalicki, R; Pasch, A; Stauffer, E; Uehlinger, DE, 2011
)
1.81
" Here we developed an electrical cell-substrate impedance sensing system (ECIS) capable of continuously measuring the dosage and time response of human proximal tubular epithelial (HK2) cells exposed to four drugs throughout the experimental period."( Use of cellular electrical impedance sensing to assess in vitro cytotoxicity of anticancer drugs in a human kidney cell nephrotoxicity model.
Cheng, J; Mitchelson, K; Wang, L; Xie, F; Xing, W; Xu, Y, 2012
)
0.38
" Dosage adjustment and close follow-up of patients' acid-base status after STS initiation is necessary."( Severe anion gap acidosis associated with intravenous sodium thiosulfate administration.
Albright, R; Kashani, K; Lee, S; Mao, M; Qian, Q, 2013
)
0.64
" Although many recent case reports have shown exceptional results and healing with the use of sodium thiosulphate, we did not experience any change in the poor prognosis of our patients with the use of this drug, at a dosage of 5 g thrice weekly endovenously."( Calciphylaxis in dialysis patients, a severe disease poorly responding to therapies: report of 4 cases.
Aldi, M; Cantelli, S; Gaddoni, G; Misciali, C; Odorici, G; Patrizi, A; Savoia, F; Tampieri, E; Tampieri, G, 2013
)
0.39
" Intravenous sodium thiosulfate was given in a dosage of 12."( Sodium thiosulfate is effective in calcific uremic arteriolopathy complicating chronic hemodialysis.
Bardin, T; Ea, HK; Malbos, S; Ureña-Torres, P, 2016
)
2.25
"Eight patients, of whom two without related renal risk factors, received STS treatment in different dosing schemes."( Sodium thiosulfate as a treatment for calciphylaxis: A case series.
Bourgeois, P; De Haes, P, 2016
)
1.88
" Although STS therapy, together with other treatment modalities, seems to improve disease outcome, more studies focusing on optimal dosing schemes and duration of treatment are necessary."( Sodium thiosulfate as a treatment for calciphylaxis: A case series.
Bourgeois, P; De Haes, P, 2016
)
1.88
" Numerous side-effects prompted dosage adjustment to 10 g intravenously daily."( Severe early-onset manifestations of pseudoxanthoma elasticum resulting from the cumulative effects of several deleterious mutations in ENPP1, ABCC6 and HBB: transient improvement in ectopic calcification with sodium thiosulfate.
Bourrat, E; Kauffenstein, G; Leftheriotis, G; Martin, L; Navasiolava, N; Nitschke, Y; Omarjee, L; Rutsch, F; Vanakker, OM; Verschuere, S; Vignon, MD, 2020
)
0.74
" Further research is needed in the field of establishing optimal dosing and frequency."( Sodium-Thiosulfate Induced Life-Threatening Metabolic Acidosis Limiting Treatment of Calciphylaxis.
George, T; Sohal, R, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (8 Product(s))

Product Categories

Product CategoryProducts
Other5
Plant-based foods and beverages, Plant-based foods, Cereals and potatoes, Cereals and their products1
Desserts, Aides culinaires, Puddings, Préparations pour desserts, Préparations pour entremets1
Beauty & Personal Care1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Enriched instant gritsPlant-based foods and beverages, Plant-based foods, Cereals and potatoes, Cereals and their productsferric phosphate2024-02-11
Golden shoestring potatoesOtherannatto2024-02-12
Basis Sensitive Skin Bar Soap -- 4 ozBasisBeauty & Personal Carecyclopentadecanolide, glycerin, sodium thiosulfate, titanium dioxide2024-11-29 10:47:42

Roles (3)

RoleDescription
antidote to cyanide poisoningA role borne by a molecule that acts to counteract or neutralize the deleterious effects of cyanide.
nephroprotective agentAny protective agent that is able to prevent damage to the kidney.
antifungal drugAny antifungal agent used to prevent or treat fungal infections in humans or animals.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
inorganic sodium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1388985Protection against cisplatin-induced ototoxicity in human assessed as hearing loss administered 6 hrs post cisplatin treatment (Rvb = 56.4%)2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.
AID1388984Protection against cisplatin-induced toxicity in cancer patient assessed as survival administered 6 hrs post cisplatin treatment (Rvb = 84%)2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (949)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990307 (32.35)18.7374
1990's150 (15.81)18.2507
2000's143 (15.07)29.6817
2010's241 (25.40)24.3611
2020's108 (11.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 107.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index107.90 (24.57)
Research Supply Index7.00 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index199.51 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (107.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials46 (4.38%)5.53%
Reviews86 (8.19%)6.00%
Case Studies177 (16.86%)4.05%
Observational4 (0.38%)0.25%
Other737 (70.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (50)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma [NCT03127774]Phase 230 participants (Anticipated)Interventional2017-09-22Recruiting
A Comparative Study of the Efficacy of Intralesional Sodium Thiosulfate Versus Intralesional Normal Saline for the Treatment of Dystrophic and Idiopathic Calcinosis Cutis, A Double-Blind Randomized Placebo-Controlled Trial [NCT03639779]Phase 45 participants (Actual)Interventional2018-11-02Terminated(stopped due to Time and resource constraints)
Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Doses of DB-020 in Patients Receiving Cisplatin [NCT04262336]Phase 122 participants (Actual)Interventional2020-02-21Completed
A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen [NCT00074165]Phase 217 participants (Actual)Interventional2003-01-31Terminated(stopped due to Lack of accrual)
Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction With Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects With Anaplastic Oligodendroglioma [NCT00303849]Phase 1/Phase 233 participants (Actual)Interventional2005-09-15Completed
A Phase II Feasibility Study of Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate Followed ny Adjuvant ALIMTA/Cisplatin [NCT00165503]Phase 216 participants (Actual)Interventional2004-04-30Terminated(stopped due to lack of acurral)
A Pilot, Randomized, Self-controlled Study of the Effects of Intratympanic Sodium Thiosulfate on the Degree of Hearing Loss in Patients Receiving Cisplatin Therapy [NCT01369641]1 participants (Actual)Interventional2011-08-24Terminated(stopped due to Poor accrual)
Pilot Study : Effect of Sodium Thiosulfate on Urine Chemistries of Hypercalciuric Stone Formers [NCT01088555]10 participants (Actual)Interventional2009-11-30Completed
Randomized Controlled Trial to Test the Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer [NCT02281006]Phase 213 participants (Actual)Interventional2015-01-01Terminated(stopped due to poor accrual)
A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk Features [NCT05382338]Phase 3225 participants (Anticipated)Interventional2023-02-20Recruiting
Cisplatin and Sodium Thiosulfate Otoprotection With or Without SAHA/Vorinostat Histone Deacetylase Inhibition for Relapsed/Refractory Hepatoblastoma and Other Embryonal Tumors [NCT05756660]Early Phase 133 participants (Anticipated)Interventional2023-03-01Recruiting
Randomized Double Blind Placebo Controlled Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy Followed by a Single Armed Extension Phase to Prospectively Observe Lesion Progression in the Presence of Sodiu [NCT02527213]Phase 340 participants (Actual)Interventional2015-01-30Terminated(stopped due to Company decision)
The Effect of Sodium Thiosulfate Treatment on Vascular Calcification in End Stage Renal Failure Patients [NCT00568399]48 participants (Actual)Interventional2007-12-31Completed
A Prospective Study of Heated Intra-Peritoneal Chemotherapy (H.I.P.E.C.) With Doxorubicin and Cisplatin in Pediatric Patients With Pelvic and Abdominal Tumors. The TOAST IT Trial (Trial Of Adjuvant Surgical Treatment With Intraperitoneal Chemotherapy) [NCT04213794]Early Phase 143 participants (Anticipated)Interventional2019-11-08Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial With a Single Arm run-in Period to Evaluate the Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985 [NCT04983238]Phase 1/Phase 248 participants (Actual)Interventional2022-01-10Completed
A Phase II Study of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation With Cisplatin [NCT04541355]Phase 216 participants (Actual)Interventional2020-10-14Completed
The Treatment Effect of Intravenous Sodium Thiosulfate on Coronary Calcification in Patients on Hemodialysis [NCT00720772]Phase 250 participants (Anticipated)Interventional2008-07-31Completed
Phase II Clinical Trial of Patients With High-Grade Glioma Treated With Intra-Arterial Carboplatin-Based Chemotherapy, Randomized to Treatment With or Without Delayed Intravenous Sodium Thiosulfate as a Potential Chemoprotectant Against Severe Thrombocyto [NCT00075387]Phase 248 participants (Actual)Interventional2003-03-07Active, not recruiting
Hydrogen Sulfate Guided Therapy With STS for COVID-19 Patients in Need of Critical Care: The H4COVID Open-label, Randomized, Triple-arm Trial [NCT05277285]Phase 230 participants (Anticipated)Interventional2022-04-01Recruiting
In Vivo Evaluation of Tumor Neurogenesis in Gastrointestinal Diseases by Topical Submucosal Chromoendoscopy [NCT05232357]Early Phase 1100 participants (Anticipated)Interventional2022-03-01Recruiting
Efficacy and Tolerance of Sodium Thiosulfate Injection After Ultrasound-guided Percutaneous Irrigation of Calcific Tendinopathy of the Rotator Cuff [NCT02538939]Phase 217 participants (Actual)Interventional2015-12-02Completed
Phase I/II Study of Intra-Arterial Melphalan Given With Intra-Arterial Carboplatin, Osmotic Blood-Brain Barrier Disruption and Delayed Otoprotective Sodium Thiosulfate for Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors [NCT00983398]Phase 1/Phase 217 participants (Actual)Interventional2009-07-09Active, not recruiting
A Phase II Feasibility Study of Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate [NCT00165516]Phase 285 participants (Actual)Interventional2004-01-31Completed
A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis (STS-CALC) [NCT01918904]Phase 20 participants (Actual)Interventional2013-09-30Withdrawn(stopped due to PI decided not to proceed with this project. No participants were enrolled.)
Phase I Dose Escalation Study of N-Acetylcysteine Administered in Conjunction With Carboplatin, Cyclophosphamide, and Etoposide Phosphate BBBD, in Children With Malignant Brain Tumors [NCT00238173]Phase 12 participants (Actual)Interventional2004-12-31Terminated(stopped due to OHSU IRB closed study to further enrollment 2/17/2006)
A Phase I Trial of Extrapleural Pneumonectomy/Pleurectomy Decortication, Intrathoracic/Intraperitoneal Hyperthermic (IOHC) Cisplatin and Gemcitabine With Intravenous Amifostine and Sodium Thiosulfate Cytoprotection for Patients With Resectable Malignant P [NCT00571298]Phase 1141 participants (Actual)Interventional2007-11-30Completed
The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy [NCT01008631]19 participants (Actual)Interventional2009-09-30Completed
Better Evidence and Translation for Calciphylaxis [NCT05018221]Phase 3350 participants (Anticipated)Interventional2021-08-26Recruiting
Efficacy of Sodium Thiosulfate in Shoulder Pain in Calcific Tendinitis of the Rotator Cuff [NCT04251832]Phase 280 participants (Anticipated)Interventional2020-01-01Recruiting
Evaluation of Thiosulfate in End Stage Renal Disease and Kidney Transplantation [NCT04292184]Phase 118 participants (Actual)Interventional2021-03-21Completed
A Multi-centre Open-label Randomised Phase III Trial of the Efficacy of Sodium Thiosulphate in Reducing Ototoxicity in Patients Receiving Cisplatin Chemotherapy for Standard Risk Hepatoblastoma [NCT00652132]Phase 3116 participants (Actual)Interventional2007-12-15Completed
Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin and Intravenous Sodium Thiosulfate in the Multimodality Treatment of Malignant Pleural Mesothelioma [NCT00165555]Phase 170 participants (Actual)Interventional1999-08-31Completed
Groningen Intervention Study for the Preservation of Cardiac Function With Sodium Thiosulfate After ST-segment Elevation Myocardial Infarction [NCT02899364]Phase 2380 participants (Anticipated)Interventional2018-07-20Active, not recruiting
Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology [NCT03092518]Phase 227 participants (Actual)Interventional2017-06-05Active, not recruiting
A Compassionate Use Program to Provide Access to Sodium Thiosulfate for the Protection From Cisplatin-Induced Hearing Loss in Children Who Had Standard-risk Hepatoblastoma [NCT04132882]0 participants Expanded AccessAvailable
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies [NCT04847063]Phase 160 participants (Anticipated)Interventional2021-10-19Recruiting
A Phase I/II Pilot Study of Patients With Brain Metastasis Secondary to Breast Cancer Treated With Methotrexate and Carboplatin in Conjunction With Blood-Brain Barrier Disruption, With Concurrent Trastuzumab in HER-2 Positive Patients [NCT00397501]Phase 1/Phase 20 participants (Actual)Interventional2013-10-31Withdrawn(stopped due to after original approval, IRB closed enrollment; major revisions required to re-open.)
A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial [NCT03150420]Phase 329 participants (Actual)Interventional2017-05-24Terminated(stopped due to "Inability to accrue subjects that met the exclusion criterion Any prior (within the past 30 days) or current Sodium Thiosulfate treatment.")
A Phase I/II Study of Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Treated With Methotrexate/BBBD, and Adding Rituximab (an Anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen [NCT00293475]Phase 1/Phase 281 participants (Anticipated)Interventional2005-10-14Active, not recruiting
A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children [NCT00716976]Phase 3131 participants (Actual)Interventional2008-06-23Completed
Safety and Tolerability of Sodium Thiosulfate in Patients Presenting With an Acute Coronary Syndrome Undergoing Coronary Angiography Via Trans-radial Approach: a Dose-escalation Study. [NCT03017963]Phase 1/Phase 218 participants (Actual)Interventional2017-10-06Completed
A Phase II Study of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Gastric Carcinomatosis or Positive Cytology [NCT02092298]Phase 221 participants (Actual)Interventional2014-05-08Completed
An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis [NCT03267277]Phase 2/Phase 314 participants (Actual)Interventional2017-10-05Active, not recruiting
The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy: a Prospective, Non-inferiority, Randomized Controlled Trial [NCT04764643]140 participants (Actual)Interventional2020-02-01Completed
Phase I Pharmacokinetic Pilot Study to Investigate the Bioavailability and Tolerability of Three Different Oral Formulations of Sodium Thiosulfate [NCT02624479]Phase 10 participants (Actual)Interventional2018-12-31Withdrawn(stopped due to Formulations could never be successfully produced)
A Phase 3 Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy Incorporating a Randomized Assessment of Sodium Thiosulfate as Otoprotection for Children With Localized Disease, and Respons [NCT04478292]Phase 3330 participants (Anticipated)Interventional2021-03-01Recruiting
National Follow-up of Dialysis Patients With Sodium Thiosufate-treated Calciphylaxis Under Temporary Use Authorization [NCT03146793]600 participants (Anticipated)Observational2017-05-01Recruiting
Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma [NCT01833832]Phase 211 participants (Actual)Interventional2013-04-12Completed
A Multicenter Randomized Phase II Clinical Trial of the Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy [NCT05129748]Phase 292 participants (Anticipated)Interventional2023-02-15Recruiting
Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis [NCT01572844]Phase 23 participants (Actual)Interventional2012-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00074165 (1) [back to overview]Number of Participants With a Complete Response Rate to Chemotherapy Regimen Assessed by Radiographic Response at 2 Years.
NCT00568399 (1) [back to overview]Change in Annualized Coronary Calcium Volume Score After Treatment With Sodium Thiosulfate.
NCT00716976 (8) [back to overview]Change in Hearing Thresholds For Key Frequencies at 1000 hz
NCT00716976 (8) [back to overview]Change in Hearing Thresholds For Key Frequencies at 2000 hz
NCT00716976 (8) [back to overview]Change in Hearing Thresholds For Key Frequencies at 4000 hz
NCT00716976 (8) [back to overview]Change in Hearing Thresholds For Key Frequencies at 500 hz
NCT00716976 (8) [back to overview]Change in Hearing Thresholds For Key Frequencies at 8000 hz
NCT00716976 (8) [back to overview]Event-Free Survival (EFS)
NCT00716976 (8) [back to overview]Incidence of Hearing Loss
NCT00716976 (8) [back to overview]Overall Survival (OS)
NCT01572844 (5) [back to overview]Change in Size of Dermatomyositis-associated Calcinosis Area on Lesions as Measured by a Difference in Plain Film (X-ray) Studies.
NCT01572844 (5) [back to overview]Change in Dermatomyositis-associated Calcinosis of a Single Lesion by Assessing Its Hardness as Measured by a Difference in Durometer (Rex Durometer Model 1600, Type OO) Measurements.
NCT01572844 (5) [back to overview]Change in Dermatomyositis-associated Calcinosis of a Single Lesion by Assessing Its Severity as Measured by a Difference in Patient Calcinosis Visual Analog Scales.
NCT01572844 (5) [back to overview]Change in Dermatomyositis-associated Calcinosis of a Single Lesion by Assessing Its Severity as Measured by a Difference in Physician Calcinosis Visual Analog Scales.
NCT01572844 (5) [back to overview]Change in Patient Functionality and/or Quality of Life.
NCT01833832 (5) [back to overview]Intraperitoneal Progression Free Survival (PFS)
NCT01833832 (5) [back to overview]Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)
NCT01833832 (5) [back to overview]Number of Patients With Treatment Related Morbidity Following the Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) Procedure
NCT01833832 (5) [back to overview]Percentage of Participants Who Survived 5-years Post Treatment
NCT01833832 (5) [back to overview]The Functional Assessment of Cancer Therapy-Colorectal Quality of Life (FACT-G) (QOL) Score Prior to Surgery, 6 Weeks After Surgery, and 3 Months After Surgery
NCT02092298 (2) [back to overview]Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy
NCT02092298 (2) [back to overview]Overall Survival (OS) From the First Laparoscopic HIPEC
NCT03639779 (3) [back to overview]Visual Analog Scale (VAS) for Pain
NCT03639779 (3) [back to overview]Lesion Size
NCT03639779 (3) [back to overview]Physician Global Assessment (PGA)

Number of Participants With a Complete Response Rate to Chemotherapy Regimen Assessed by Radiographic Response at 2 Years.

Per RECIST criteria (v1.1) and assessed by magnetic resonance imaging (MRI): Complete response (CR), Disappearance of all target lesions. (NCT00074165)
Timeframe: 2 years

InterventionParticipants (Number)
Rituximab and Carboplatin1

[back to top]

Change in Annualized Coronary Calcium Volume Score After Treatment With Sodium Thiosulfate.

We will compare the annualized coronary calcium volume score obtained at the baseline CT of the coronary arteries with another CT obtained of the same coronary arteries following 5 months of sodium thiosulfate treatment. (NCT00568399)
Timeframe: 5 months

Interventionmm3/year (Geometric Mean)
Sodium Thiosulfate6.6

[back to top]

Change in Hearing Thresholds For Key Frequencies at 1000 hz

Mean change in hearing threshold (post-pre) at 1000 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin

InterventionDecibels (Mean)
STS Arm (Sodium Thiosulfate Treatment)-0.676
Observation Arm-0.319

[back to top]

Change in Hearing Thresholds For Key Frequencies at 2000 hz

Mean change in hearing threshold (post-pre) at 2000 hz (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin

InterventionDecibels (Mean)
STS Arm (Sodium Thiosulfate Treatment)-1.18
Observation Arm0.638

[back to top]

Change in Hearing Thresholds For Key Frequencies at 4000 hz

Mean change in hearing threshold (post-pre) at 4000 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin

InterventionDecibels (Mean)
STS Arm (Sodium Thiosulfate Treatment)1.05
Observation Arm9.58

[back to top]

Change in Hearing Thresholds For Key Frequencies at 500 hz

Mean change in hearing threshold (post-pre) at 500 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin

InterventionDecibels (Mean)
STS Arm (Sodium Thiosulfate Treatment)-1.45
Observation Arm-1.11

[back to top]

Change in Hearing Thresholds For Key Frequencies at 8000 hz

Mean change in hearing threshold (post-pre) at 8000 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin

InterventionDecibels (Mean)
STS Arm (Sodium Thiosulfate Treatment)9.73
Observation Arm17.0

[back to top]

Event-Free Survival (EFS)

Proportion of patients event free at 4 years following enrollment. See EFS outcome measure description. (NCT00716976)
Timeframe: 4 years after enrollment

InterventionPercentage probability (Number)
STS Arm (Sodium Thiosulfate Treatment)53.7
Observation Arm61.4

[back to top]

Incidence of Hearing Loss

Hearing loss defined by comparing hearing sensitivity at follow up evaluation relative to baseline measurements using ASHA criteria. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin

InterventionPatients (Number)
STS Arm (Sodium Thiosulfate Treatment)14
Observation Arm31

[back to top]

Overall Survival (OS)

Proportion of patients alive free at 4 years following enrollment. See OS outcome measure description. (NCT00716976)
Timeframe: 4 Years after enrollment

InterventionPercentage probability (Number)
STS Arm (Sodium Thiosulfate Treatment)69.6
Observation Arm82.0

[back to top]

Change in Size of Dermatomyositis-associated Calcinosis Area on Lesions as Measured by a Difference in Plain Film (X-ray) Studies.

Change in dermatomyositis-associated calcinosis as measured by a difference in centimeters in plain film (x-ray) studies. X rays were compared between baseline and final assessment for any changes. (NCT01572844)
Timeframe: Change from Visit 2 to Visit 12 (week 20)

Interventioncm (Mean)
Treatment Lesion0
No Treatment Lesion0

[back to top]

Change in Dermatomyositis-associated Calcinosis of a Single Lesion by Assessing Its Hardness as Measured by a Difference in Durometer (Rex Durometer Model 1600, Type OO) Measurements.

Change in dermatomyositis-associated calcinosis of a single lesion by assessing its hardness as measured by a difference in durometer (Rex durometer Model 1600, Type OO) measurements. The range of a durometer is from 0 to 100. The higher the durometer reading, the harder the lesion. Improvement in the lesion hardness would result in a negative change over time. (NCT01572844)
Timeframe: Change from Baseline (Visit 1) at Final Assessment (Visit 12, week 20).

,
Interventionpercentage of change (Number)
Subject 1Subject 2
No Treatment Lesion-18.423.8
Treatment Lesion-35.87.4

[back to top]

Change in Dermatomyositis-associated Calcinosis of a Single Lesion by Assessing Its Severity as Measured by a Difference in Patient Calcinosis Visual Analog Scales.

Change in dermatomyositis-associated calcinosis of a single lesion by assessing its severity as measured by a difference in Patient Calcinosis Visual Analog Scales. The scale ranges from zero (0) to ten (10). Zero (0) being no evidence of disease activity and ten (10) being extremely active or severe disease activity. A negative change would indicate improvement in the disease activity. A positive change would indicate worsening of disease activity. (NCT01572844)
Timeframe: Change from Visit 2 to Visit 12 (week 20)

,
InterventionPercentage of change (Number)
Subject 1Subject 2
No Treatment Lesion136.51.9
Treatment Lesion104.70

[back to top]

Change in Dermatomyositis-associated Calcinosis of a Single Lesion by Assessing Its Severity as Measured by a Difference in Physician Calcinosis Visual Analog Scales.

Change in dermatomyositis-associated calcinosis of a single lesion by assessing its severity as measured by a difference in Physician Calcinosis Visual Analog Scales. The Visual Analog Scale range is from zero (0) to ten (10). Zero (0) being no evidence of disease activity and ten (10) being extremely active or severe disease activity. A negative percent change indicates improvement in the lesion. (NCT01572844)
Timeframe: Change from Visit 2 to Visit 12 (week 20)

,
Interventionpercentage change (Number)
Subject 1Subject 2
No Treatment Lesion3.32.0
Treatment Lesion-38.0-53.1

[back to top]

Change in Patient Functionality and/or Quality of Life.

This will be assessed through the use of the Dermatology Life Quality Index (DLQI), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (CHAQ), Manual Muscle Testing (MMT8), and range of motion evaluations. DLQI index scores range from 0 to 30. The higher the score, the more quality of life is impaired.Change in scores from baseline to final assessment yielding a negative percent change indicate an improvement in DLQI. HAQ scales range from 0 to 3. The higher the score, the greater the disability. Change in scores from baseline to final assessment yielding a negative percent change indicate an improvement in the HAQ. MMT8 testing results in a score between 0 and 150. The higher the score, the more normal the function of the muscle. A positive percent change would indicate an improvement in MMT8 testing results. (NCT01572844)
Timeframe: Change from Visit 1 to Visit 12 (week 20)

Interventionpercentage of change from baseline (Number)
DLQI : Subject 1DLQI : Subject 2HAQ : Subject 1HAQ : Subject 2MMT8 : Subject 1MMT8 : Subject 2
Treatment Lesion-37.557.1-44.403.4-6.7

[back to top]

Intraperitoneal Progression Free Survival (PFS)

Amount of time subject survives without intraperitoneal disease progression after treatment. Disease progression is defined as imageable tumor nodules or increasing ascites persistent on computed tomography (CT) scan as interpreted by the official interpretation of the imaging studies. (NCT01833832)
Timeframe: Amount of time subject survives without intraperitoneal disease progression after treatment, an average of 17 months

InterventionMonths (Median)
Cytoreductive Surgery Followed by HIPEC19

[back to top]

Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01833832)
Timeframe: Date treatment consent signed to date off study, approximately 34 months and 28 days.

InterventionParticipants (Count of Participants)
Cytoreductive Surgery Followed by HIPEC8

[back to top] [back to top]

Percentage of Participants Who Survived 5-years Post Treatment

Percentage of participants who are alive after treatment. (NCT01833832)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Cytoreductive Surgery Followed by HIPEC66.7

[back to top]

The Functional Assessment of Cancer Therapy-Colorectal Quality of Life (FACT-G) (QOL) Score Prior to Surgery, 6 Weeks After Surgery, and 3 Months After Surgery

QOL characteristics were collected using The Functional Assessment of Cancer Therapy-Colorectal Quality of Life (QOL) questionnaire version 4, a validated survey that interrogates physical, emotional, functional, and social well being in cancer related issues on a 5-point scale. Scores range from 0 to 108 points. Higher scores are consistent with a better outcome. (NCT01833832)
Timeframe: Prior to surgery, 6 weeks post surgery, and 3 months post surgery

Interventionscores on a scale (Mean)
Prior to surgery6 weeks after surgery3 months after surgery
Cytoreductive Surgery Followed by HIPEC82.676.480.2

[back to top]

Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy

Primary objective of study is to assess overall survival (OS) in subjects with stage IV gastric cancer representing positive cytology or imaging occult carcinomatosis after laparoscopic hyperthermic intraperitoneal chemotherapy administration. Overall survival measured from time of laparoscopic HIPEC. Patterns of tumor recurrence and survival assessed by reviewing routine surveillance CT scans. Overall survival time estimated using the Kaplan-Meier method. (NCT02092298)
Timeframe: Between the second and sixth week after treatment, up to 5 years

InterventionMonths (Median)
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)30.2

[back to top]

Overall Survival (OS) From the First Laparoscopic HIPEC

Primary objective of study is to assess overall survival (OS) in subjects with stage IV gastric cancer representing positive cytology or imaging occult carcinomatosis after the first laparoscopic HIPEC. Patterns of tumor recurrence and survival assessed by reviewing routine surveillance CT scans. Overall survival time estimated using the Kaplan-Meier method. (NCT02092298)
Timeframe: From the day of surgery, until the last day of follow up, until death, up to 5 years

InterventionMonths (Median)
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)20.3

[back to top]

Visual Analog Scale (VAS) for Pain

The VAS for pain is used to assess the pain associated with the lesion. The pain will be recorded as a number from 1 (no pain) to 10 (severe pain). (NCT03639779)
Timeframe: 3 months

Interventionscore on a scale (Mean)
Sodium Thiosulfate3.6
Saline Solution2.6

[back to top]

Lesion Size

The lesion size is measured in square centimeters. (NCT03639779)
Timeframe: 3 months

,
Interventioncm^2 (Mean)
Baseline3 Months
Saline Solution1.83.0
Sodium Thiosulfate2.83

[back to top]

Physician Global Assessment (PGA)

The PGA will be done by the physician to assess appearance and changes in the lesion. The lesion will be assigned a score from 0 (clear) to 4 (severe). (NCT03639779)
Timeframe: 3 months

,
Interventionscore on a scale (Mean)
Baseline3 Month
Saline Solution43.25
Sodium Thiosulfate43

[back to top]